Investors and Media, George Washington | May 3, 2018
Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies
Company is focusing on lysosomal storage disorders, liver and muscle diseases, inflammation and neurodegeneration CAMBRIDGE, Mass., May 3, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, launched today with $58.5 million in Series A funding from Third Rock Ventures. Casma is pioneering novel strategies […]
